BPC-157 vs Liraglutide
Side-by-side comparison of key properties, dosing, and research.
Recovery & Repair
BPC-157GLP-1 / Weight Loss AgonistsFat Loss & Metabolic
Liraglutide- Summary
- BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in the stomach. It is one of the most extensively researched healing peptides, known for accelerating tissue repair, reducing inflammation, and protecting the gastrointestinal tract.
- Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
- Half-Life
- 4–6 hours
- ~13 hours (once-daily dosing)
- Admin Route
- SubQ, IM, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 200–500 mcg
- Start 0.6 mg, titrate to 3 mg
- Frequency
- Once daily
- Once daily
- Key Benefits
- Accelerates wound healing and tissue repair
- Reduces inflammation throughout the body
- Protects and heals the gastrointestinal tract
- Supports tendon and ligament healing
- Promotes bone and joint health
- May protect organs from toxins and injury
- Supports gut-brain axis function
- Counteracts NSAID-induced gut damage
- Promotes weight loss (5–10% average)
- Reduces appetite and caloric intake
- Improves blood glucose control (HbA1c reduction)
- Reduces cardiovascular events in T2DM (LEADER trial)
- Slows gastric emptying
- FDA-approved for T2DM and chronic weight management
- Cardioprotective effects shown in clinical trials
- May improve fatty liver (NAFLD/NASH)
- Side Effects
- Injection site discomfort
- Nausea (rare)
- Headache (rare)
- Dizziness (rare)
- Nausea (very common, especially initially)
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- +5 more
- Stacks With
- —
- —